| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6280959 | NOVARTIS | Metal complexes |
Oct, 2018
(5 years ago) | |
| US7473686 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(2 years ago) | |
| US7452874 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(2 years ago) | |
| US7160870 | NOVARTIS | Thrombopoietin mimetics |
Nov, 2022
(1 year, 5 months ago) | |
| US7547719 | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jul, 2025
(1 year, 2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6280959 (Pediatric) | NOVARTIS | Metal complexes |
Apr, 2019
(4 years ago) | |
| US7790704 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(2 years ago) | |
| US7332481 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(2 years ago) | |
|
US7790704 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(2 years ago) | |
|
US7332481 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(2 years ago) | |
|
US7452874 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(2 years ago) | |
|
US7473686 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(2 years ago) | |
|
US7160870 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
May, 2023
(11 months ago) | |
| US7795293 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
May, 2023
(11 months ago) | |
|
US7795293 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Nov, 2023
(5 months ago) | |
|
US7547719 (Pediatric) | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jan, 2026
(1 year, 8 months from now) | |
| US8062665 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
| US8052993 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
| US8071129 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
| US8828430 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
| US8052995 | NOVARTIS | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
| US8052994 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Aug, 2027
(3 years from now) | |
|
US8062665 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) | |
|
US8828430 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) | |
|
US8052993 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) | |
|
US8052994 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) | |
|
US8071129 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) | |
|
US8052995 (Pediatric) | NOVARTIS | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) | |
Promacta is owned by Novartis.
Promacta contains Eltrombopag Olamine.
Promacta has a total of 28 drug patents out of which 14 drug patents have expired.
Expired drug patents of Promacta are:
- US6280959*PED
- US7790704
- US7332481
- US7790704*PED
- US7332481*PED
- US7452874*PED
- US7473686*PED
- US7160870*PED
- US7795293
- US7795293*PED
- US6280959
- US7473686
- US7452874
- US7160870
Promacta was authorised for market use on 20 October, 2011.
Promacta is available in tablet;oral dosage forms.
Promacta can be used as treatment of thrombocytopenia in adult and pediatric patients 6 years and older with chronic immune (idiopathic) thrombocytopenia (itp), treatment of idiopathic thrombocytopenic purpura (itp), combination with immunosuppressive therapy for first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia, patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy, treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp), treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy.
Drug patent challenges can be filed against Promacta from 26 February, 2021.
The generics of Promacta are possible to be released after 01 February, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-210) | Nov 16, 2025 |
| New Indication(I-711) | Jun 11, 2018 |
| New Dosing Schedule(D-149) | Jun 11, 2018 |
| Pediatric Exclusivity(PED) | Feb 26, 2022 |
| Orphan Drug Exclusivity(ODE-75) | Aug 26, 2021 |
| New Indication(I-664) | Nov 16, 2015 |
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
| Orphan Drug Exclusivity(ODE) | Nov 20, 2015 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
NCE-1 date: 26 February, 2021
Market Authorisation Date: 20 October, 2011
Treatment: Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); Patients with severe aplastic anemia who have had an insufficien...
Dosage: TABLET;ORAL
PROMACTA family patents
